What the research shows
TB-500 and the Wolverine stack: what the evidence shows
Sources verified against the primary documents on 9 July 2026.
The short answer
TB-500 is a short synthetic fragment (LKKTETQ) of thymosin beta-4, a naturally occurring protein. The human clinical trials routinely cited as evidence for TB-500 were run on full-length recombinant thymosin beta-4 — for dry eye disease and cardiac indications — not on the fragment. No randomized human trial has tested TB-500 itself for musculoskeletal healing, and the "Wolverine stack" is a nickname, not a study.
Key facts
- TB-500
- A 7-amino-acid fragment: LKKTETQ
- Thymosin beta-4
- The full 43-amino-acid protein
- Human trials for Tβ4
- Yes — dry eye, phase I safety
- Human trials for TB-500
- None for musculoskeletal healing
The substitution at the heart of the marketing
This is the most important thing on the page, and almost nobody says it. TB-500 and thymosin beta-4 are not the same molecule. Thymosin beta-4 (Tβ4) is a 43-amino-acid protein the body makes. TB-500 is a synthetic 7-residue fragment of it, LKKTETQ, believed to carry the actin-binding activity.
Real human trials of full-length recombinant Tβ4 exist. A phase 2 trial of Tβ4 eye drops in severe dry eye showed statistically significant improvement in symptoms and corneal staining, and a first-in-human phase I study established a safety profile for recombinant Tβ4. Those trials are frequently cited on pages selling TB-500.
They are not evidence for TB-500. They are evidence for a different, larger molecule, delivered by a different route, for a different indication. Citing them for injectable TB-500 in a torn hamstring is a category error, and it is committed constantly.
Check which molecule the trial used
When a page cites a “thymosin beta-4 clinical trial” as support for TB-500, look at the study drug. If it is RGN-259, or “recombinant thymosin beta-4”, the trial did not test the product you are being sold.
The “Wolverine stack”
Pairing BPC-157 with TB-500 acquired the nickname because of the comic-book character’s regenerative healing. The name tells you the expectation, and the name is not evidence.
The rationale offered is that the two act through complementary repair pathways — angiogenesis for one, actin regulation and cell migration for the other. That is a mechanistically reasonable thing to say and it has never been tested as a combination in a randomised human trial. Combining two compounds with no human efficacy data does not produce one compound with human efficacy data.
It does, reliably, double your exposure to whatever contamination, mislabelling, or dosing error is present in the grey market you bought both from.
Regulatory status
Thymosin beta-4 fragment (LKKTETQ), explicitly identified by FDA as TB-500, previously sat in Category 2 of bulk substances that may present significant safety risks. Its nomination has since been withdrawn by the nominators, which removes it from that table without making it eligible for compounding or approving it for anything.
For anyone competing under an anti-doping code, both TB-500 and BPC-157 fall within prohibited classes, and modern analytical workflows detect peptidic doping agents in blood. A "research use only" label offers no protection against an adverse analytical finding.
Compounds referenced in this guide
TB-500 (Thymosin Beta-4) is used or studied for may aid recovery and repair and related healing and regeneration goals. Potential benefits and safety depend on indication, formulation, dose, and medical supervision.
BPC-157 is used or studied for may promote tissue healing and related healing and regeneration goals. Potential benefits and safety depend on indication, formulation, dose, and medical supervision.
A two-compound injury-recovery stack used to support soft-tissue repair, tendon recovery, and regeneration-focused wellness protocols.
Frequently asked questions
Is TB-500 the same as thymosin beta-4?
No. Thymosin beta-4 is a 43-amino-acid protein. TB-500 is a synthetic 7-amino-acid fragment of it (LKKTETQ). Human clinical trials have been conducted on full-length recombinant thymosin beta-4, not on the fragment, and results from one do not automatically transfer to the other.
Are there human trials of TB-500?
Not for musculoskeletal healing. The human trials commonly cited — a phase 2 dry-eye study and a first-in-human phase I safety study — used full-length recombinant thymosin beta-4, administered for different indications by different routes.
Does the Wolverine stack work?
The combination of BPC-157 and TB-500 has never been tested in a randomized human trial. Neither component has demonstrated efficacy for musculoskeletal healing in humans individually. The name derives from a comic-book character, which is a fair summary of the evidentiary basis.
Will TB-500 show up on a drug test?
Peptides in this class fall within categories prohibited by the World Anti-Doping Agency, and published analytical workflows detect peptidic doping agents in blood matrices. Whether a specific panel screens for it depends on the panel, but legality and detectability are separate questions from anti-doping compliance.
Sources
Every link below was checked and resolved before publication. Where a claim could not be traced to a primary document, we left it out.
- Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial. Cornea. 2015
- A first-in-human, randomized, double-blind, single- and multiple-dose phase I study of recombinant thymosin beta-4. J Cell Mol Med. 2021
- Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026
- FDA — Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks
- WADA — The Prohibited List
Written by Pepperz Editorial and not medically reviewed — see our editorial standards. Educational reference only. Pepperz does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing recommendations.